journal
MENU ▼
Read by QxMD icon Read
search

Medical Oncology

journal
https://www.readbyqxmd.com/read/29340905/expression-of-vhl-tumor-suppressor-mrna-and-mir-92a-in-papillary-thyroid-carcinoma-and-their-correlation-with-clinical-and-pathological-parameters
#1
Lidija Todorović, Boban Stanojević, Vesna Mandušić, Nina Petrović, Vladan Živaljević, Ivan Paunović, Aleksandar Diklić, Vladimir Saenko, Shunichi Yamashita
A growing body of evidence suggests a role of the von Hippel-Lindau (VHL) tumor suppressor gene in the progression of papillary thyroid carcinoma (PTC). Our previous study of VHL in PTCs showed that lower VHL expression was associated with aggressive tumor features, but we found no evidence for VHL downregulation through common genetic or epigenetic modifications. Several studies pointed to a role of microRNA-92a (miR-92a) in the regulation of VHL expression in different cancers. In the present study, we examined the expression levels of VHL mRNA and miR-92a in 42 pairs of PTCs and matched non-tumor thyroid tissues by means of quantitative RT-PCR...
January 16, 2018: Medical Oncology
https://www.readbyqxmd.com/read/29302760/genetic-polymorphisms-associated-with-adverse-reactions-of-molecular-targeted-therapies-in-renal-cell-carcinoma
#2
REVIEW
Kazuhiro Yamamoto, Ikuko Yano
The prognosis of patients with metastatic renal cell carcinoma has drastically improved due to the development of molecular-targeted drugs and their use in clinical practice. However, these drugs cause some diverse adverse reactions in patients and sometimes affect clinical outcomes of cancer therapy. Therefore, predictive markers are necessary to avoid severe adverse reactions, to establish novel and effective prevention methods, and to improve treatment outcomes. Some genetic factors involved in these adverse reactions have been reported; however, perspectives on each adverse response have not been integrated yet...
January 4, 2018: Medical Oncology
https://www.readbyqxmd.com/read/29288421/first-line-treatment-with-bendamustine-and-rituximab-in-patients-with-intermediate-high-risk-splenic-marginal-zone-lymphomas
#3
Roberto Castelli, Luigi Bergamaschini, Giorgio Lambertenghi Deliliers
Splenic marginal zone lymphomas (SMZLs) are rare indolent B cell neoplasms that affect the spleen, bone marrow, and blood. Although they have an indolent course in the majority of patients, who have a median survival of 8-10 years, ∼ 30% may experience a worse outcome. The prognostic criteria of progression are lymph node and extra-nodal involvement, high lymphocyte counts, anaemia, and thrombocytopenia. The treatment of SMZLs include a "wait and watch strategy", splenectomy, and alkylating agents ± rituximab...
December 29, 2017: Medical Oncology
https://www.readbyqxmd.com/read/29274027/chemotherapy-and-echocardiographic-indices-in-patients-with-non-hodgkin-lymphoma-the-onco-echo-study
#4
Katarzyna Mizia-Stec, Marek Elżbieciak, Maciej T Wybraniec, Monika Różewicz, Artur Bodys, Wojciech Braksator, Zbigniew Gąsior, Piotr Gościniak, Tomasz Hryniewiecki, Jarosław Kasprzak, Andrzej Wojtarowicz, Barbara Zdziarska, Edyta Płońska-Gościniak
The cardiotoxicity of chemotherapy (CTx) for non-Hodgkin's lymphomas is not well recognized. In order to facilitate individual risk counseling for patients, we analyzed the effect of CTx on echocardiographic indices in regard to clinical data in patients treated for non-Hodgkin's lymphoma (NHL). A prospective multicenter ONCO-ECHO trial included 67 patients with NHL (45 patients with DLBCL (diffuse large B cell lymphoma) and 22 with non-DLBCL). Patients received standard CTx, primarily R-CHOP, CHOP, R-COP and COP regimens...
December 22, 2017: Medical Oncology
https://www.readbyqxmd.com/read/29255938/immunotherapy-in-triple-negative-breast-cancer
#5
REVIEW
Heather Katz, Mohamed Alsharedi
Breast cancer can be classified based on the expression or lack of expression of protein receptors including estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth receptor 2 (Her2). The basal molecular subtype is mostly made up of breast cancers that do not express ER/PR or Her2, triple-negative breast cancers (TNBC) (Bertucci et al. in Int J Cancer 123(1):236, 2008). TNBC tends to be more aggressive as there are no approved targeted treatments and the only treatment option currently is cytotoxic chemotherapy...
December 18, 2017: Medical Oncology
https://www.readbyqxmd.com/read/29248965/effectiveness-of-olanzapine-in-patients-who-fail-therapy-with-aprepitant-while-receiving-highly-emetogenic-chemotherapy
#6
Nikita Mehra, Prasanth Ganesan, Trivadi S Ganesan, Surendran Veeriah, Abirami Boopathy, Venkatraman Radhakrishnan, Manikandan Dhanushkodi, Swaminathan Rajaraman, Sevaluxmy Ganesharajah, Tenali Gnana Sagar
Chemotherapy-induced nausea-vomiting (CINV) compromises the quality of life of patients with cancer. We present data on the effectiveness of olanzapine after failure of aprepitant in patients receiving highly emetogenic chemotherapy (HEC). A single-center prospective study was conducted, where patients ≥ 18 years who failed aprepitant, palonosetron, dexamethasone (APD) received olanzapine, palonosetron and dexamethasone (OPD) in the subsequent cycle of HEC. Failure of APD was defined as occurrence of ≥ grade 2 acute and/or delayed nausea ± vomiting...
December 16, 2017: Medical Oncology
https://www.readbyqxmd.com/read/29234902/correction-to-molecular-imaging-of-advanced-thyroid-cancer-iodinated-radiotracers-and-beyond
#7
Prasanna Santhanam, Lilja B Solnes, Steven P Rowe
The original version of this article unfortunately contained a mistake. The middle name of the author Steven B. Rowe is incorrect. The corrected name is Steven P. Rowe.
December 12, 2017: Medical Oncology
https://www.readbyqxmd.com/read/29234899/correction-to-ten-year-results-of-accelerated-hypofractionated-adjuvant-whole-breast-radiation-with-concomitant-boost-to-the-lumpectomy-cavity-after-conserving-surgery-for-early-breast-cancer
#8
Domenico Cante, Edoardo Petrucci, Piera Sciacero, Cristina Piva, Silvia Ferrario, Silvia Bagnera, Sebastiano Patania, Guido Mondini, Massimo Pasquino, Valeria Casanova Borca, Giorgio Vellani, Maria Rosa La Porta, Pierfrancesco Franco
An error inadvertently occurred in the discussion of the original publication when citing the local relapse rates of the EORTC 22881-10882 trial ('boost vs no boost trial').
December 12, 2017: Medical Oncology
https://www.readbyqxmd.com/read/29214525/treatment-of-melanoma-with-selected-inhibitors-of-signaling-kinases-effectively-reduces-proliferation-and-induces-expression-of-cell-cycle-inhibitors
#9
Dorota Ciołczyk-Wierzbicka, Dorota Gil, Piotr Laidler
Cancer treatment often tends to involve direct targeting enzymes essential for the growth and proliferation of cancer cells. The aim of this study was the recognition of the possible role of selected protein kinases: PI3K, ERK1/2, and mTOR in cell proliferation and cell cycle in malignant melanoma. We investigated the role of protein kinase inhibitors: U0126 (ERK1/2), LY294002 (PI3K), rapamycin (mTOR), everolimus (mTOR), GDC-0879 (B-RAF), and CHIR-99021 (GSK3beta) in cell proliferation and expression of crucial regulatory cell cycle proteins in human melanoma cells: WM793 (VGP) and Lu1205 (metastatic)...
December 6, 2017: Medical Oncology
https://www.readbyqxmd.com/read/29214466/large-scale-dna-organization-is-a-prognostic-marker-of-breast-cancer-survival
#10
Martial Guillaud, Qian Ye, Sam Leung, Anita Carraro, Alan Harrison, Malcolm Hayes, Alan Nichol, Mira Keyes
Breast cancer is the leading cause of cancer-related deaths among women worldwide. We investigated whether changes in large-scale DNA organization (LDO) of tumor epithelial nuclei are an indicator of the aggressiveness of the tumor. We tested our algorithm on a set of 172 duplicates TMA cores samples coming from 95 breast cancer patients. Thirty-five patients died of breast cancer, and 60 were still alive 10 years after surgery. Duplicates cores were used to create training and test set. The TMA slides were stained with Feulgen-thionin and imaged using our in-house high-resolution Imaging system...
December 6, 2017: Medical Oncology
https://www.readbyqxmd.com/read/29214356/more-predictive-markers-were-identified-for-trastuzumab-induced-cardiotoxicity
#11
LETTER
Kadri Altundag
No abstract text is available yet for this article.
December 6, 2017: Medical Oncology
https://www.readbyqxmd.com/read/29210005/the-novel-role-of-il-37-in-prostate-cancer-evidence-as-a-promising-radiosensitizer
#12
Vivi A Ding, Ziwen Zhu, Timothy A Steele, Mark R Wakefield, Huaping Xiao, Dean Balabanov, Yujiang Fang
Prostate cancer (PCa) is the most common non-cutaneous cancer in men in the USA. Radiation therapy (RT) is widely considered the standard treatment for PCa. IL-37 is an IL-1 family member, and it has been extensively studied in immunity. However, no studies have been done regarding its potential as a radiosensitizer. This study is designed to investigate the direct effect of IL-37 on growth of DU145 and PC-3, two widely studied PCa cell lines, and to investigate whether IL-37 could be used as a radiosensitizer for PCa...
December 5, 2017: Medical Oncology
https://www.readbyqxmd.com/read/29209984/intravesical-thalidomide-boosts-bacillus-calmette-gu%C3%A3-rin-bcg-in-non-muscle-invasive-bladder-cancer-treatment
#13
Gabriela R Passos, Juliana A Camargo, Karen L Ferrari, Mário J A Saad, Amilcar C de Mattos, Leonardo O Reis
The aim of this study was to explore the efficacy of intravesical Thalidomide (immunomodulatory, anti-inflammatory and anti-angiogenic) added to BCG using an immune competent autochthonous orthotopic NMIBC animal model. Female Fischer 344 rats, 7 weeks of age, received every 2 weeks for four times, a dose of 1.5 mg/kg of N-methyl-N-nitrosourea (MNU) intravesically. The rats were randomized into four groups (n = 10 per group) to receive intravesical treatment once a week for 6 weeks as follows: control (0...
December 4, 2017: Medical Oncology
https://www.readbyqxmd.com/read/29209847/prediction-of-venous-thromboembolism-in-newly-diagnosed-patients-treated-for-lymphoid-malignancies-validation-of-the-khorana-risk-score
#14
Joanna Rupa-Matysek, Lidia Gil, Maciej Kaźmierczak, Marta Barańska, Mieczysław Komarnicki
The utility of the venous thromboembolism (VTE) risk assessment model known as the Khorana Risk Score (KRS) in patients with lymphoid malignancies receiving outpatient chemotherapy is not defined. We evaluated the association of the KRS with VTE in patients treated for diffuse large B cell lymphoma (DLBCL) or Hodgkin lymphoma (HL). Retrospective analyses were performed in 428 patients, 241 of whom were newly diagnosed with DLBCL and 187 of whom had HL. During the initial therapy, 64 (15%) patients developed VTE and 56 died during follow-up...
December 4, 2017: Medical Oncology
https://www.readbyqxmd.com/read/29209837/emerging-enzymatic-targets-controlling-angiogenesis-in-cancer-preclinical-evidence-and-potential-clinical-applications
#15
REVIEW
Biagio Ricciuti, Jennifer Foglietta, Rita Chiari, Amirhossein Sahebkar, Maciej Banach, Vanessa Bianconi, Matteo Pirro
Angiogenesis has always been considered as a fundamental therapeutic target for inhibiting tumor growth and metastasis. To date, anti-angiogenic treatments that have been approved are principally based on either administration of monoclonal antibodies targeting the vascular endothelial growth factor/vascular endothelial growth factor receptor axis or multikinase inhibitors. However, a growing body of evidence is pointing out the role of different classes of enzymes involved in tumor-driven angiogenesis, whose inhibition in preclinical models has already shown encouraging results...
December 4, 2017: Medical Oncology
https://www.readbyqxmd.com/read/29209838/imp3-expression-in-nsclc-brain-metastases-demonstrates-its-role-as-a-prognostic-factor-in-non-neuroendocrine-phenotypes
#16
Alessandro Del Gobbo, Annamaria Morotti, Anna Eleonora Colombo, Valentina Vaira, Giulia Ercoli, Chiara Pesenti, Eleonora Bonaparte, Elena Guerini-Rocco, Andrea Di Cristofori, Marco Locatelli, Alessandro Palleschi, Stefano Ferrero
Brain metastases from NSCLC are associated with a poor prognosis, and local radiotherapy is the most effective therapeutic strategy. The oncofetal protein IMP3 has been studied extensively, and evidence suggests that its expression is related to shorter overall survival and a more aggressive phenotype in solid malignancies. Here, the prognostic role of IMP3 was investigated in a cohort of patients with NSCLC brain metastases in correlation with survival and tumor histotype. A series of 42 NSCLC brain metastases samples was analyzed by tissue microarray and immunohistochemical staining for IMP3...
December 1, 2017: Medical Oncology
https://www.readbyqxmd.com/read/29209826/volumetric-modulated-arc-therapy-vmat-to-deliver-nodal-irradiation-in-breast-cancer-patients
#17
Giuseppe Carlo Iorio, Pierfrancesco Franco, Elena Gallio, Stefania Martini, Francesca Arcadipane, Sara Bartoncini, Nadia Rondi, Francesca Romana Giglioli, Ada Ala, Mario Airoldi, Michela Donadio, Corrado De Sanctis, Isabella Castellano, Umberto Ricardi
To evaluate feasibility, safety, toxicity profile and dosimetric results of volumetric modulated arc therapy (VMAT) to deliver regional nodal irradiation (RNI) after either mastectomy or breast conservation (BCS) in high-risk breast cancer patients. Between January 2015 and January 2017, a total of 45 patients were treated with VMAT to deliver RNI together with whole breast or post-mastectomy radiotherapy. The fractionation schedule comprised 50 Gy in 25 fractions given to supraclavicular and axillary apex nodes and to whole breast (after BCS) or chest wall (after mastectomy)...
November 24, 2017: Medical Oncology
https://www.readbyqxmd.com/read/29168038/ovarian-serous-carcinomas-acquire-cisplatin-resistance-and-increased-invasion-through-downregulation-of-the-high-temperature-required-protein-a2-htra2-following-repeated-treatment-with-cisplatin
#18
Hiroaki Soyama, Morikazu Miyamoto, Masashi Takano, Tadashi Aoyama, Hiroko Matsuura, Takahiro Sakamoto, Kazuki Takasaki, Mika Kuwahara, Kento Kato, Tomoyuki Yoshikawa, Hideki Iwahashi, Hitoshi Tsuda, Kenichi Furuya
High-temperature-required protein A2 (HtrA2) is one of the serine proteases related to apoptosis. HtrA2 protein expression has been associated with cisplatin resistance and poor prognosis in ovarian serous adenocarcinoma (SAC). The aim of this study was to understand the influence of HtrA2 on repeated treatment with cisplatin. The change in HtrA2 expression in 31 ovarian cancers was investigated by immunohistochemical analysis, before and after cisplatin-based chemotherapy, and the association between HtrA2 expression after chemotherapy and prognosis was analyzed...
November 22, 2017: Medical Oncology
https://www.readbyqxmd.com/read/29164397/factors-for-time-to-trastuzumab-induced-cardiotoxicity-in-breast-cancer-patients
#19
Mi Hyung Lee, Jeong Yee, Young Ju Kim, Jin Young Moon, Joo Hee Kim, Sandy Jeong Rhie, Hye Sun Gwak
Trastuzumab is a drug used for the treatment of metastatic breast cancer patients. Due to blockage of the human epidermal growth factor receptor 2 signaling in cardiac myocytes, cardiotoxicity has been observed. There are many studies that investigated risk factors for trastuzumab-induced cardiotoxicity, but no study has been published for factors on the time to cardiotoxicity. This study aimed to investigate the factors for the time to occur trastuzumab-induced cardiotoxicity. From January 2014 to December 2015, a retrospective study was performed with breast cancer patients who were treated with trastuzumab...
November 21, 2017: Medical Oncology
https://www.readbyqxmd.com/read/29164346/impact-of-prior-androgen-receptor-axis-targeted-agents-on-the-clinical-activity-of-subsequent-docetaxel-in-patients-with-metastatic-castration-resistant-prostate-cancer-comparative-assessment-between-abiraterone-acetate-and-enzalutamide
#20
Hideaki Miyake, Yuto Matsushita, Keita Tamura, Daisuke Motoyama, Toshiki Ito, Takayuki Sugiyama, Atsushi Otsuka
The objective of this study was to investigate the impact of prior treatment with androgen receptor-axis-targeted (ARAT) agents, abiraterone acetate (AA) and enzalutamide (Enz), on the activity of subsequently introduced docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC). This study included a total of 114 mCRPC patients consisting of 54 and 60 who progressed following treatment with AA and Enz, respectively, prior to the introduction of docetaxel, and compared oncological outcomes with docetaxel between these two groups...
November 21, 2017: Medical Oncology
journal
journal
32014
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"